Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Anti-cancer adenoviruses
US9187733B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9187733-B2 |
| Application number | US-201313768933-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 15, 2013 |
| Priority date | Aug 16, 2010 |
| Publication date | Nov 17, 2015 |
| Grant date | Nov 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Anti-cancer adenoviruses, methods of use and methods of making the same are provided herein.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a cancer with reduced expression or activity of p53, comprising administering an effective amount of a recombinant adenovirus that is E1B-55k impaired and E4-ORF3 impaired to a subject in need thereof, wherein the recombinant adenovirus is not replication impaired in a p53 impaired cell. 2. The method of claim 1 , wherein the cancer is lung cancer, skin cancer or breast cancer. 3. The method of claim 1 , wherein the cancer to be treated is pre-malignant breast cancer. 4. The method of claim 1 , wherein the recombinant adenovirus expresses a mutated E4-ORF3 product. 5. The method of claim 1 , wherein the recombinant adenovirus comprises an E4-ORF3 gene that is wholly or partially deleted. 6. The method of claim 1 , wherein the recombinant adenovirus expresses a mutated E1B-55k gene product. 7. The method of claim 1 , wherein the recombinant adenovirus comprises an E1B-55k gene that is wholly or partially deleted. 8. The method of claim 1 , wherein the recombinant adenovirus comprises an E4-ORF3 gene that is wholly or partially deleted and an E1B-55k gene that is wholly or partially deleted. 9. The method of claim 1 , wherein the recombinant adenovirus comprises a mutated E4-ORF3 gene and an E1B-55k gene that is wholly or partially deleted.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- C12N15/861Primary
Adenoviral vectors · CPC title
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00) · CPC title
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00) · CPC title
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9187733B2 cover?
- Anti-cancer adenoviruses, methods of use and methods of making the same are provided herein.
- Who is the assignee on this patent?
- Salk Inst For Biological Studi
- What technology area does this patent fall under?
- Primary CPC classification C12N15/861. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).